An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer

Summary

The purpose of this study is to evaluate the induction of immune responses against CV9104 administered by conventional intradermal injection or with a needle-free intradermal injection device and to assess the safety and tolerability of CV9104 administered by conventional intradermal injection versus injection with a needle-free intradermal injection device versus no injection.

Timeline

Start

2014-06

Primary completion

2016-04

Completion

2016-04

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.”

Drugs

Indications